Semaglutide
BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity
Novo Nordisk · Phase 3 · Not yet recruiting · Enrollment 352
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Group A: Bofanglutida (GZR18), | Obesity or overweight | n/r | 36 | n/r | n/r |
| Group B: Semaglutide | Obesity or overweight | n/r | 36 | n/r | n/r |